Revati Shreeniwas

Revati Shreeniwas

President bij Revati, Inc.

63 jaar
Health Technology
Consumer Services
Commercial Services

Profiel

Revati Shreeniwas is currently the President of Revati, Inc. and a Member of Continuing Medical Education, Inc. She previously worked as a Principal at Scios, Inc. and CV Therapeutics, Inc., as well as the Vice President of Clinical Research & Development at Alvine Pharmaceuticals, Inc. She also held the position of Principal at The Trustees of Columbia University in The City of New York and was a Professor at Stanford University.
Additionally, she served as the Chief Medical Officer at NeurAxon Pharma, Inc. from 2015 to 2017 and is currently the Chief Medical Officer at Bright Minds Biosciences, Inc. from 2020 to 2022.

Actieve functies van Revati Shreeniwas

BedrijvenFunctieBegin
Corporate Officer/Principal -
Revati, Inc. President 01-01-2004
Alle actieve functies van Revati Shreeniwas

Eerdere bekende functies van Revati Shreeniwas

BedrijvenFunctieEinde
BRIGHT MINDS BIOSCIENCES INC. Hoofd Techniek/Wetenschap/O&O 01-12-2022
SOLENO THERAPEUTICS, INC. Hoofd Techniek/Wetenschap/O&O 01-06-2020
Hoofd Techniek/Wetenschap/O&O 01-01-2017
Stanford University Corporate Officer/Principal -
The Trustees of Columbia University in The City of New York Corporate Officer/Principal -
Ervaring van Revati Shreeniwas in detail bekijken

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Revati Shreeniwas in detail bekijken

Connecties

14

Eerstegraads connecties

10

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Beursgenoteerde bedrijven2
SOLENO THERAPEUTICS, INC.

Health Technology

BRIGHT MINDS BIOSCIENCES INC.

Health Technology

Bedrijven in privébezit6

Health Technology

Health Technology

Revati, Inc.

Health Technology

Consumer Services

Commercial Services

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Revati Shreeniwas
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU